Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
Abstract Background Among medically ill patients treated with thromboprophylaxis, betrixaban was not associated with an increase in major bleeding compared with enoxaparin, but an increase in clinically relevant non-major (CRNM) bleeding was observed. The aim of this analysis is to desc...
Main Authors: | Megan K. Yee, C. Michael Gibson, Tarek Nafee, Mathieu Kerneis, Yazan Daaboul, Serge Korjian, Gerald Chi, Fahad AlKhalfan, Adrian F. Hernandez, Russell D. Hull, Alexander T. Cohen, Samuel Z. Goldhaber |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2019-04-01
|
Series: | TH Open |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0039-1685496 |
Similar Items
-
Incidence and risk factors of warfarin therapy complications in community hospitals, central and eastern regions, Thailand: a retrospective, multicenter, cohort study
by: Benyapha Sombat, et al.
Published: (2023-06-01) -
Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
by: Manesh R. Patel, et al.
Published: (2018-03-01) -
Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 – REGATA)
by: Ekaterina S. Kropacheva, et al.
Published: (2023-01-01) -
Venous thromboembolism and major bleeding in severe and critical COVID-19 hospitalized patients
by: Veronica Abate, et al.
Published: (2023-07-01) -
Comparison of bleeding risk scores and evaluation of major bleeding predictive factors in patients with major bleeding due to vitamin K antagonist use
by: Sinan Yildirim, et al.
Published: (2023-08-01)